文献速递心脑血管急症消化、代谢与肾脏急症

卡格列净与2型糖尿病的心血管及肾脏事件

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
PubMed 文献 · N Engl J Med · 2017-06-12
一句话结论在2型糖尿病且心血管高风险患者中,卡格列净较安慰剂降低主要心血管复合终点发生率(HR 0.86),但截肢风险增高(HR 1.97),截肢主要位于足趾或跖骨水平。

CANVAS项目整合了两项试验,共纳入10142例2型糖尿病且心血管高风险患者,随机接受卡格列净或安慰剂,平均随访188.2周。主要终点为心血管原因死亡、非致死性心肌梗死或非致死性卒中的复合终点,卡格列净组发生率为26.9/1000患者年,安慰剂组为31.5/1000患者年(HR 0.86;95%CI 0.75-0.97;非劣效性P<0.001;优效性P=0.02)。虽按预设假设检验顺序肾脏结局未视为有统计学意义,但白蛋白尿进展(HR 0.73;95%CI 0.67-0.79)及eGFR持续下降40%、需肾脏替代治疗或肾性原因死亡的复合结局(HR 0.60;95%CI 0.47-0.77)显示可能获益。截肢风险增加(6.3 vs 3.4/1000患者年;HR 1.97;95%CI 1.41-2.75),主要位于足趾或跖骨水平。

要点

  • 在2型糖尿病且心血管高风险患者中,卡格列净较安慰剂降低主要心血管复合终点(心血管死亡、非致死性心梗或非致死性卒中)发生率:26.9 vs 31.5/1000患者年,HR 0.86(95%CI 0.75-0.97)。
  • 卡格列净组截肢风险较安慰剂组增高:6.3 vs 3.4/1000患者年,HR 1.97(95%CI 1.41-2.75),截肢主要位于足趾或跖骨水平。
  • 白蛋白尿进展风险卡格列净组低于安慰剂组:HR 0.73(95%CI 0.67-0.79);eGFR持续下降40%、需肾脏替代治疗或肾性原因死亡的复合结局HR 0.60(95%CI 0.47-0.77),但按预设假设检验顺序肾脏结局未视为有统计学意义。
  • 平均随访188.2周,卡格列净的不良反应与既往报告的风险一致,除截肢风险增加外。
  • 卡格列净在2型糖尿病且心血管高风险人群中降低心血管事件风险,但需权衡截肢风险,尤其是足趾或跖骨水平截肢。

适用人群与场景

  • 2型糖尿病且心血管高风险患者,共10142例,平均年龄63.3岁,女性35.8%,糖尿病平均病程13.5年,65.6%有心血管疾病史。

研究设计与关键结果

  • CANVAS项目整合两项试验,共10142例2型糖尿病且心血管高风险患者,随机接受卡格列净或安慰剂,平均随访188.2周。
  • 主要终点(心血管原因死亡、非致死性心肌梗死或非致死性卒中的复合终点)发生率卡格列净组26.9/1000患者年 vs 安慰剂组31.5/1000患者年,HR 0.86(95%CI 0.75-0.97),非劣效性P<0.001,优效性P=0.02。
  • 白蛋白尿进展HR 0.73(95%CI 0.67-0.79);eGFR持续下降40%、需肾脏替代治疗或肾性原因死亡的复合结局HR 0.60(95%CI 0.47-0.77),但按预设假设检验顺序肾脏结局未视为有统计学意义。
  • 截肢发生率卡格列净组6.3/1000患者年 vs 安慰剂组3.4/1000患者年,HR 1.97(95%CI 1.41-2.75),截肢主要位于足趾或跖骨水平。
  • 不良反应与既往报告的卡格列净相关风险一致,除截肢风险增加外。

证据类型、等级与局限

  • 证据类型:随机对照试验整合分析(CANVAS项目,整合两项试验)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在2型糖尿病且心血管高风险患者中,卡格列净降低主要心血管复合终点发生率,但增加截肢风险(主要位于足趾或跖骨水平),临床决策需权衡心血管获益与截肢风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. Methods The CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Results The mean age of the participants was 63.3 years, 35.8% were women, the mean duration of diabetes was 13.5 years, and 65.6% had a history of cardiovascular disease. The rate of the primary outcome was lower with canagliflozin than with placebo (occurring in 26.9 vs. 31.5 participants per 1000 patient-years; hazard ratio, 0.86; 95% confidence interval [CI], 0.75 to 0.97; P<0.001 for noninferiority; P=0.02 for superiority). Although on the basis of the prespecified hypothesis testing sequence the renal outcomes are not viewed as statistically significant, the results showed a possible benefit of canagliflozin with respect to the progression of albuminuria (hazard ratio, 0.73; 95% CI, 0.67 to 0.79) and the composite outcome of a sustained 40% reduction in the estimated glomerular filtration rate, the need for renal-replacement therapy, or death from renal causes (hazard ratio, 0.60; 95% CI, 0.47 to 0.77). Adverse reactions were consistent with the previously reported risks associated with canagliflozin except for an increased risk of amputation (6.3 vs. 3.4 participants per 1000 patient-years; hazard ratio, 1.97; 95% CI, 1.41 to 2.75); amputations were primarily at the level of the toe or metatarsal. Conclusions In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal. (Funded by Janssen Research and Development; CANVAS and CANVAS-R ClinicalTrials.gov numbers, NCT01032629 and NCT01989754 , respectively.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017. PMID: 28605608. doi:10.1056/NEJMoa1611925

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。